Preemptive genotyping for personalized medicine: Design of the right drug, right dose, right timedusing genomic data to individualize treatment protocol

Mayo Clinic Proceedings

Volumn 89, Issue 1, 2014, Pages 25-33

  Bielinski, Suzette J ^a   Olson, Janet E ^a   Pathak, Jyotishman ^a   Weinshilboum, Richard M ^b,c   Wang, Liewei ^b   Lyke, Kelly J ^a   Ryu, Euijung ^a   Targonski, Paul V ^d   Van Norstrand, Michael D ^a   Hathcock, Matthew A ^e   Takahashi, Paul Y ^f   McCormick, Jennifer B ^e   Johnson, Kiley J ^a   Maschke, Karen J ^b   Rohrer Vitek, Carolyn R ^e   Ellingson, Marissa S ^g   Wieben, Eric D ^c,d   Farrugia, Gianrico ^e   Morrisette, Jody A ^f   Kruckeberg, Keri J ^a,b   Bruflat, Jamie K ^d,e   Peterson, Lisa M ^f   Blommel, Joseph H ^a   Skierka, Jennifer M ^a,c   Ferber, Matthew J ^a,e   Black, John L ^a   Baudhuin, Linnea M ^a   Klee, Eric W ^c   Ross, Jason L ^d   Veldhuizen, Tamra L ^f   Schultz, Cloann G ^e   Caraballo, Pedro J ^g   Freimuth, Robert R ^h   Chute, Christopher G ^a   Kullo, Iftikhar J ⁱ   more..

^a MAYO CLINIC   (United States)

^b Center for Individualized Medicine   (United States)

^c Division of Primary Care Internal Medicine   (United States)

^d Division of General Internal Medicine   (United States)

^e Department of Biochemistry and Molecular Biology ^*  (United States)

^f Division of Gastroenterology   (United States)

^g Division of Cardiovascular Diseases   (United States)

^h ALBERT LEA EYE CLINIC   (United States)

ⁱ HASTINGS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2D6; HLA B ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MERCAPTOPURINE; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TAMOXIFEN; TRAMADOL;

ADULT; ARTICLE; CLINICAL DECISION SUPPORT; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; CYP2C19 GENE; CYP2D6 GENE; DECISION SUPPORT SYSTEM; DRUG EFFICACY; DRUG GENE INTERACTION; DRUG INTERACTION; ELECTRONIC MEDICAL RECORD; FEMALE; GENE; GENE INTERACTION; GENE LOCUS; GENE SEQUENCE; HEALTH CARE PLANNING; HIGH RISK PATIENT; HLA B GENE; HUMAN; IFNL3 GENE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; RIGHT PROTOCOL; SLCO1B1 GENE; TPMT GENE;

EID: 84893097016     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.10.021     Document Type: Article

References (18)

1. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-537.
2. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004;3(9):739-748.
3. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet. 2006;7:223-245.
4. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144-1153.
5. US Food andDrugAdministration. Table of pharmacogenomic biomarkers in drug labels. http://www.fda.gov/drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378.htm. Updated June 19, 2013. Accessed July 10, 2013.
6. Farrugia G, Weinshilboum RM. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther. 2013;94(2):204-206.
7. Pharmacogenomics Research Network. http://www.pgrn.org. Accessed November 26, 2013.
8. Electronic Medical Records and Genomics (eMERGE) Network. http://emerge.mc.vanderbilt.edu. Accessed November 26, 2013.
9. Kho AN, Pacheco JA, Peissig PL, et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med. 2011;3(79):79re1.
10. Olson JE, Ryu E, Johnson KJ, et al. The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc. 2013; 88(9):952-962.
11. Gordon AS, Smith JD, Xiang Q, et al. PGRNseq: a new sequencing-based platform for high-throughput pharmacogenomic implementation and discovery. Abstract presented at the 62nd Annual Meeting of the American Society of Human Genetics: November 6-8, 2012; San Francisco, CA. Program #244. http://www.ashg.org/2012meeting/abstracts/fulltext/f120122669.htm. Accessed May 25, 2013.
12. Wilke RA, Ramsey LB, Johnson SG, et al; Clinical Pharmacogenomics Implementation Consortium (CPIC). The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92(1):112-117.
13. Rocca WA, Yawn BP, St. Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87(12):1202-1213.
14. New York Department of Health. Oncologydmolecular and cellular tumor markers: next generation sequencing (NGS) guidelines for somatic genetic variant detection. http://www.wadsworth.org/labcert/TestApproval/forms/NextGenSeq-ONCO- Guidelines.pdf. Updated November 26, 2012. Accessed October 10, 2013.
15. Altman RB. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet. 2007;39(4):426.
16. Flockhart DA. Drug interactions: cytochrome p450 drug interaction table. Indiana University School of Medicine website. http://medicine.iupui.edu/ clinpharm/ddis/clinical-table/. Updated July 12, 2013. Accessed August 1, 2013.
17. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464-467.
18. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388-394.